Abstract. High-mobility group protein box 1 (HMGB1) released from dying tumor cells promotes tumor progression, on the other hand HMGB1 activates dendritic cells and triggers anti-neoplastic response of T-cells in chemotherapy and radiotherapy. HMGB1 expression is up-regulated in many kinds of tumors. To investigate HMGB1 expression in non-small cell lung cancer, 63 patients were enrolled and tumor tissues were collected with matched normal lung tissues. HMGB1 mRNA and protein levels were quantified with real-time PCR, Western blots and immunohistochemistry. The HMGB1 expression in tumor tissue was lower than in matched normal lung tissue at mRNA levels (Paired t-test, t<0.001) and the down-regulation in stage III-IV patients was also significantly greater than one in stage I-II (one-way ANOVA, p=0.005). At protein level, HMGB1 expression was also down-regulated. Low HMGB1 expression in non-small cell lung cancer may explain the poor therapeutical outcome during chemotherapy and radiotherapy.
Introduction
High-mobility group protein box 1 (HMGB1) is a member of the high-mobility group protein superfamily with a 27 kDa molecular mass. As a non-histone chromatin protein, HMGB1 plays an important role in DNA architecture and transcriptional regulation (1) . When released actively by immune cells or passively by necrotic cells to extracellular environment, HMGB1 functions to recruit inflammatory cells and to mediate signals between natural killer cells, dendritic cells and macrophages by interacting with AGER (advanced glycosylation end product-specific receptor) and/or TLR2/4 (Toll-like receptor) to activate the NF-κB pathway. As a damage-associated molecular pattern molecule (DAMP), HMGB1 promotes inflammation, stimulates tissue repair and is involved in many pathological conditions, such as sepsis, arthritis, and ischemia-reperfusion injury (2) (3) (4) .
HMGB1 was found to be related to tumor development from the discovery of its action in the modulation of neurite outgrowth many years ago (5) and now more and more studies show that HMGB1-AGER interactions mediate cancer cell's proliferation, invasion and migration (6, 7) . Mitola et al demonstrated that HMGB1 could stimulate tumor angiogenesis in vitro and in vivo (8) . As a so-called danger-signaling cytokine, HMGB1 promotes tumor progression. Upregulated expression of HMGB1 has been found in many tumor types, including breast cancer (9, 10) , hepatocellular carcinoma (11), melanoma (12, 13) , gastric cancer (14) , nonHodgkin lymphoma (15) and colorectal cancer (16) .
However, a previous study revealed that the relationship between HMGB1 and tumor had an additional totally opposite aspect. Apetoh et al revealed that during chemotherapy and radiotherapy, dying cancer cells secreted HMGB1, that acted on the Toll-like receptor 4 (TLR4) expressed on the dendritic cells and efficiently processed and crosspresented the antigen through TLR4 and its adaptor MyD88 from dying tumor cells to activate the tumor antigen-specific T-cell immunity that was essential for therapy (17) . They found that breast cancer patients who carried a loss-offunction TLR4 allele, the key figure of the immune response, relapsed more quickly after radiotherapy and chemotherapy than those carrying the normal TLR4 allele. They also found that the depletion of HMGB1 from doxorubicin-or oxaliplatintreated tumor cells using neutralizing antibodies or HMGB1-specific siRNAs compromised the efficacy of anti-tumor vaccination. Therefore HMGB1 has a paradoxical dual effect: on one hand it promotes tumor progress, on the other hand it triggers protective anti-cancer responses of T-cells.
Up-regulated HMGB1 expression is found in almost all type of tumors detected together with advanced glycosylation ONCOLOGY REPORTS 22: 535-539, 2009 535 The expression of high-mobility group protein box 1 correlates with the progression of non-small cell lung cancer end product-specific receptor (AGER) expression, supporting the idea that HMGB1 is a danger-signaling cytokine. Interestingly, lung cancer is the exception with reduced expression of AGER (18) . This prompted us to investigate the HMGB1 expression in lung cancer. HMGB1 expression was quantified in non-small cell lung cancer. To our surprise, as a whole, HMGB1 expression was down-regulated and the down-regulation was related with tumor stage. RNA extraction and cDNA synthesis. Total RNA was isolated from frozen tissue with TRIzol (Invitrogen). With random hexamer primers, 2 μg RNA was reverse transcribed to cNDA with PrimeScript™ first-strand cDNA synthesis kits (Takara).
Materials and methods

Patients
Real-time PCR.
Primers for HMGB1 and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were designed and synthesized by Takara Inc. The basic information on the primers including gene name, NCBI reference, forward primer, reverse primer, product size (bp) was as follows, respectively: HMGB1, NM_002128, TGCAGATGACAAG CAGCCTTATG, TTTCAGCCTTGACAACTCCCTTT, 128; GAPDH, NM_002046, GCACCGTCAAGGCTGAGAAC, TGGTGAAGACGCCAGTGGA, 138. Real-time PCR was performed in triplicate for each sample in a 25-μl reaction mixture, which consisted of template DNA (2 μl) and primers (0.2 μM), ROX Reference Dye II (1x), dH 2 O (9.0 μl) and SYBR ® Premix Ex Taq (1x, SYBR Premix Ex Taq Kit, Takara). PCR was performed on Stratagene Mx3005P instrument using the following thermal settings: one cycle of 10 sec at 95˚C and 45 cycles of 5 sec at 95˚C and 20 sec at 60˚C. The relative expression ratio (RR) of HMGB1 gene was calculated based on the Ct comparative with a reference gene (GAPDH) in a sample.
Western blot analysis. For protein analysis, samples were homogenized in lysis buffer (0.1% SDS, 50 mM Tris-HCl, pH 7.5, 1% NP-40, 150 mM NaCl, 1 mM Triton X-100, 1 mM EDTA) containing complete protease inhibitor (PMSF+P8340). Protein concentration was measured by the BCA protein assay (Sigma). A total of 100 μg protein was separated by 10-5% SDS-PAGE. Protein was then transferred to nitrocellulose membrane and these were saturated by incubating for 2 h with 5% non-fat dry milk in PBS/0.1% Tween-20 in 37˚C. The membranes were then incubated with the rabbit polyclonal anti-HMGB1 antibody (Abcom) overnight at 4˚C. After three washes (5 min each) with PBS/0.1% Tween-20, membranes were incubated with anti-rabbit immunoglobulin coupled to peroxidase (Abcom) in 37˚C. After 1 h of incubation the membranes were washed four times (5 min each) with PBS/ 0.1% Tween-20 and the blots were developed using the chemiluminescence procedure (Amersham Bioscence). Polyclonal anti-ß-actin antibody served as control.
Immunohistochemistry of paraffin-embedded sections. IHC staining was performed using standard protocols. Briefly, all paraffin sections, 4-μm in thickness, were baked for 1 h at 60˚C. Sections were deparaffinized with xylene and rehydrated with graded ethanol to distilled water. Sections were submerged in citrate buffer (pH 6.0) and subjected to microwave treatment, then treated with 3% H 2 O 2 for 15 min to block the endogenous peroxidase. Rabbit polyclonal anti-HMGB1 antibody (Abcom) (1:100) was incubated with the sections for 1.5 h at 37˚C. After washing with PBS, the sections were incubated with intensifier for 20 min at room temperature. Secondary goat anti-rabbit polyclonal antibody was incubated with sections for 30 min at room temperature. For colour reactions, diaminobenzidine (DAB) was used. As negative controls, the antibody was replaced by normal rabbit serum.
Statistical analysis. Data were expressed as mean ± standard deviation with the range given in parentheses. Statistical analysis was performed using the t-tests, ANOVA and paired t-test when data were normally distributed. All statistical procedures were performed using SPSS (Version 15.0 SPSS Inc, Chicago). Values of p<0.05 were considered as statistically significant.
Results
Characteristics of the NSCLC patients. In 63 patients (median age 58 yrs) who underwent operative treatment (47 cases for lobectomy, 9 for pneumonectomy, 4 for segmental resection and 3 for sleeve lobectomy), the tumor size was 4.26±1.26 cm (range: 1-9 cm). Forty-nine patients underwent sequential therapy after surgery resections and 3 patients with N2 stage underwent induction chemotherapy before resections (the three patients degraded to N0-1 after the induction chemotherapy). Thirty-four patients (54%) were smokers. Other characteristics are summarized in Table I .
Expression of HMGB1 in lung cancer tissues. The relative mRNA level of HMGB1 gene (HMGB1 per GAPDH, mean ± SD) is 1.09±0.53 in TT, 2.24±1.14 in TF and 2.15±1.76 in HC, respectively. HMGB1 in TT was significantly lower than in HC (n=13) and TF (one-way ANOVA, p<0.001). Paired t-test showed that HMGB1 in TT was significantly lower than in TF (p<0.001) (Fig. 1A) . In summary, HMGB1 mRNA level is overall down-regulated in tumor samples of NSCLC patients. In addition, 33 paired samples were analyzed by Western blots. In protein level, the expression of HMGB1 was also down-regulated in tumor tissues. The protein level of HMGB1 (HMGB1 per ß-actin, mean ± SD) is 0.64±0.43 in TT, 0.90±0.54 in TF and 0.91±0.55 in HC, respectively. Paired t-test showed that HMGB1 in TT was significantly lower than in TF (p=0.004). HMGB1 in TT was also lower than in HC (n=13), but in one-way ANOVA, p=0.073 (Fig. 1B  and C) .
Down-regulation of the HMGB1 expression correlates with progression of NSCLC.
The association between HMGB1 expression and clinical characteristics of patients was analyzed. There were no significant correlations between HMGB1 expression and gender, age, pathological classifications (p>0.05). However, III-IV stage patients show significantly less expression level of HMGB1 than those in I-II stage (p=0.005) (Fig. 2) . Of the patients in stage III, 3 patients with N2 stage who underwent induction chemotherapy before resections show no difference with others in HMGB1 expression levels.
Distribution of HMGB1 in the lung tissues of NSCLC.
Ten paired samples (3 pairs are adenocarcinoma and the other 7 pairs are squamous cell carcinoma) were analyzed in IHC. One adenocarcinoma sample had 30-50% positively stained, two squamous cell carcinoma samples had <10% positively stained and seven tumor samples had >50% tumor cells positively stained. All matched normal tissues were positively stained. In normal lung alveolar epithelial cells, the nucleolus was strongly stained and the cytoplasm stained moderately. However, in tumor tissues, only stained nucleolus could be found (Fig. 3) .
Discussion
We showed that HMGB1 expression was decreased in human non-small cell lung cancer tissues. At mRNA level, the HMGB1 expression decreased greatly and the differences between tumor tissue, matched normal tissue and healthy control were significant. At protein level, HMGB1 expression also decreased in tumor tissues in spite of several exceptions, but the difference was not significant. Some steroid hormones are linked to the transcriptional regulation of HMGB1 gene, including glucocorticoids, estrogens and progestins. In macrophages and monocytes, HMGB1 transcription is regulated by IFN-Á, TNF-· and TGF-ß (19). Table I . Characteristics of lung cancer patients in this study. In cancer cells, down-regulation of some gene expression is commonly associated with the mutations or aberrant DNA methylation of the promoter. There are no previous studies on the promoter mutations of HMGB1, but one large CpG island (2000 bp) does exist in the beginning of HMGB1 gene including the promoter and enhancer. More studies need to be done to find out whether aberrant DNA methylation exists and reduces the expression of HMGB1 in lung cancer. Posttranscriptional regulations of HMGB1 gene are important for its function. After translation, HMGB1 undergoes some modifications, such as phosphorylation, ADP ribosylation, and acetylation. Acetylation of HMGB1 potentially modulates HMGB1 to interact with other proteins both in nucleus and extracellularly (20) . In many cancers, HMGB1 is over-expressed depending on AGER, with which HMGB1 triggers a signal channel to boost the cancer-like oncoproteins (21) . However, in our study, we found HMGB1 expression was overall downregulated in non-small cell lung cancer tissue not only at mRNA level but also at protein level. Interestingly, also making one exception, AGER is down-regulated in NSCLC. Why is HMGB1 gene expression different in NSCLC? The more perplexing question is how HMGB1 can act differently in cancers. HMGB1 has a paradoxical dual effect in cancer: on one hand it works like an oncoprotein to promote tumor progress and on the other hand it functions like an anticancer protein to trigger the protective anti-cancer T-cell responses. One explanation sounds reasonable: In most growing solid cancers, hypoxia kills cancer cells and dying cells release HMGB1 steadily, with which tumors are supported for proliferation, migration and neoangiogenesis. During chemotherapy and radiotherapy, large amounts of tumor cells die and massive HMGB1 release is rapid, so dendritic cells are recruited and activated, anti-neoplastic Tcell response is triggered. The kinetics of HMGB1 release (pulsed, when elicited by anti-neoplastic treatments and continuous, in progressively growing neoplasms) and the amount released in the unit of time (substantially higher when elicited by anti-neoplastic treatment) probably makes the difference (22) . In lung cancer, apparently the AGER-HMGB1 signal channel is not dominant and some other pathways take its place to support cancers for proliferation, migration and neoangiogenesis.
-------------------------------------------------
During chemotherapy and radiotherapy, low HMGB1 expression indicates low release of HMGB1 protein, which may be one explanation of poorer therapeutical outcome in lung cancer than in other cancers. The evidence is that downregulation of HMGB1 mRNA is especially stronger in patients with stage III-IV than those in stage I-II in our study. Analogously, Akaike et al found that in gastric cancer, the prognosis of the low HMGB-1 group (n=41) was significantly poorer than that of the high HMGB-1 group (n=35, p<0.05) (23) . Our three patients who had a PR response in induction chemotherapy before the sections did not show particularly high expression of HMGB1. More patients should be included to survey the relationship between HMGB1 expression and outcome of chemotherapy or radiotherapy. Additional study should be conducted to find out whether low expression of HMGB1 can be used as an indicator for advanced progression or poor prognosis in lung cancer. While in human nasopharyngeal carcinoma, increased expression of HMGB1 is associated with advanced progression and poor prognosis (24) . Several potential therapeutic methods targeting increased HMGB1 may come into clinical application soon, applying HMGB1-neutralizing antibodies (25) , tuncated forms of HMGB1 (26) , ethyl pyruvate (27) and sAGER (28) to block or replace HMGB1, inhibit HMGB1 release and block HMGB1-AGER signal channel. However, we suppose that it may be helpful to introduce exogenetic HMGB1 into the tumor mass during chemotherapy and radiotherapy especially in non-small cell lung cancer.
